Found 411 articles
Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream
Illumina, Inc. announced that its inaugural Illumina Genomics Forum, being held in San Diego from September 28 through October 1, is sold out.
23andMe Holding Co., a leading consumer genetics and research company, appointed Daniel Chu as Chief Product Officer.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it will feature Anne Wojcicki, co-founder and CEO of personal genomics company 23andMe, at its inaugural Illumina Genomics Forum on October 1.
The global Consumer Genomics market is forecast to reach USD 6.58 Billion by 2027, according to a new report by Reports and Data.
Latest Study on “Genomics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
Latest Study on “DNA & RNA Banking Services Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
Personalized Medicine Market 2022 Industry Growth, Top Key Players, Segmentation and Forecast till 2030
Latest Study on “Personalized Medicine Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
Genetic Testing Services Market: Increased Diagnosis Rate of the Rare Diseases and its Growing Incidence is Estimated to Boost the Market
Transparency Market Research has published a new report titled, ‘Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.According to the report, the global genetic testing services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027.
23andMe Holding Co., a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the first quarter of its fiscal year 2023, which ended June 30, 2022.
According to Vision Research Reports, the UAE genetic testing market size was estimated at around USD 20.36 million in 2021 and it is projected to hit around USD 121.2 million by 2030, growing at a CAGR of 21.92% from 2022 to 2030.
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday, August 8, 2022.
Genealogy Products and Services Gaining Traction in Forensics Thereby Impacting Market Growth at 11.4% CAGR By 2024, States Fact.MR Study
Fact.MR – a market research and competitive intelligence provider: The genealogy products and services market is likely to be valued at over US$ 3 billion in 2019.
BlackRock and QLS Advisors LLC, a life sciences technology and advisory firm, have announced a partnership through BlackRock Systematic to develop data-driven investment solutions to help accelerate biomedical innovation.
Nucleus Genomics, a next-generation consumer genetic testing and analysis company, has raised $14 million in a new funding round led by Alexis Ohanian's Seven Seven Six.
Human Microbiome Market: Rising Prevalence of Gastrointestinal and Metabolic Disorders Drive Market Growth
Wilmington, Delaware, United States, Transparency Market Research Inc.: Microbiome is a genetic component of various microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body.
According to Vision Research Reports, the next-generation sequencing market size is projected to be worth around US$ 38.5 billion by 2030 from valued at US$ 6.8 billion in 2020 and is anticipated to grow at a CAGR of 14.6% from 2022 to 2030.
According to Report, the global next-generation sequencing market size is projected to be worth around US$ 38.5 billion by 2030 and is expected to grow at a CAGR of 14.6% from 2022 to 2030.
Members include pioneers of cancer biology and computational biology who have discovered key drivers of the disease and advanced the discovery of new therapies.
23andMe Holding Co. reported its financial results for the fourth quarter and full year of fiscal year 2022, which ended March 31, 2022.
23andMe Holding Co., a leading consumer genetics and research company, announced that it will report financial results for the fiscal year 2022 fourth quarter and full year after the market closes on Thursday, May 26, 2022.